Neurology Clinical Trials Market Report and Forecast (2025-2034)

The global neurology clinical trials market was valued at USD 6.50 Billion in 2024, driven by the increasing innovations in neurology research activities across the globe. The market is anticipated to grow at a CAGR of 6.30% during the forecast period of 2025-2034 to achieve a value of USD 11.97 Billion by 2034 .

Neurology Clinical Trials Market Overview

Neurology clinical trials are research studies that evaluate the safety and effectiveness of treatments for disorders affecting the brain, spinal cord, and nervous system. These trials test new drugs, devices, or interventions for conditions like Alzheimer’s, Parkinson’s, epilepsy, and multiple sclerosis. Conducted in phases, they involve patient volunteers and follow strict regulatory guidelines to ensure ethical standards and accurate data. Advances in imaging, biomarkers, and digital tools are improving trial outcomes. Neurology trials are vital for developing innovative therapies and understanding complex neurological diseases that impact millions worldwide.

Neurology Clinical Trials Market Growth Drivers

Surge in FDA Approvals Based on Trial Outcomes Impacting the Market Value

Growing global stroke prevalence and increasing demand for faster, more effective thrombolytic therapies are major drivers of market growth in neurology clinical trials. For instance, in March 2025, the US FDA approved a fast-acting thrombolytic agent for acute ischaemic stroke, following favourable results from the 1,600-patient AcT trial and corroborating findings from the TRACE-2 study in China. The new agent demonstrated similar safety and efficacy compared to the standard therapy, while offering a significantly quicker administration time. This regulatory milestone is poised to expand clinical trial activity for stroke therapies and thrombectomy-combination approaches, further enhancing market value by fostering drug development for time-sensitive neurological emergencies.

Increasing Focus on Addressing Unmet Needs to Elevate Neurology Clinical Trials Market Demand

Rising awareness of patient-centric care and the growing need for gender-specific treatment guidance is strengthening the focus of neurology clinical trials. For instance, at the American Epilepsy Society Meeting in December 2024, new data highlighted significant gaps in epilepsy care for women of childbearing age. The study found that access to timely, accurate, and relevant treatment information remains limited, particularly regarding pregnancy and epilepsy. This contributes to confusion, anxiety, and a lack of informed decision-making. These findings underscore the urgency of inclusive and targeted clinical epilepsy research. Consequently, future neurology trials are expected to incorporate diverse patient perspectives, leading to the development of more accessible, tailored therapies and enhancing global market value.

Neurology Clinical Trials Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Development of Novel Stroke Drugs Driving Market Growth

A surge in stroke-related neurological disorders is pushing demand for innovative treatments, propelling the neurology clinical trials market. For instance, in October 2025, UConn School of Medicine received over USD 2 million in follow-up NIH funding to advance testing of a small-molecule, anti-inflammatory stroke drug targeting the P2X4 receptor. This novel, brain-permeable compound has shown neuroprotective effects and the ability to repair post-stroke brain damage in animal models. As this therapy progresses towards human trials, it is expected to spark increased funding and activity in early-phase stroke-related trials, thereby driving significant growth in the market.

Emphasis on R&D Activities to Boost Neurology Clinical Trials Market Growth

Clinical trial momentum is growing around stroke therapies with demonstrable late-stage efficacy. For instance, in October 2024, Phase III data from the CHARM study revealed that CIRARA (IV glyburide) led to a 55% relative increase in patients regaining independent walking ability 12 months after a large hemispheric infarction, especially when combined with thrombectomy. Originally dropped by Biogen, the drug’s revived success under Remedy Pharmaceuticals underscores the market potential of re-examined compounds. The strong long-term outcomes are likely to encourage increased sponsor confidence and investment in neurology trials, fuelling further development and diversity within the stroke therapy pipeline.

Rise in Regulatory Approvals for Early Drug Development to Influence Neurology Clinical Trials Market Size

Increasing FDA approvals for early-phase testing are validating the global importance of stroke-focused neurology clinical trials. For instance, in January 2024, the FDA authorised AB126, a University of Georgia-developed therapeutic, to enter Phase 1b/2a clinical trials for ischaemic stroke patients. Administered intravenously post-clot removal, the drug offers hope for patients not eligible for traditional therapies. Its entrance into clinical stages signifies growing trust in innovative approaches and opens opportunities for novel interventions. As AB126 moves forward, it is poised to attract additional capital and partnerships, significantly enhancing the market value and visibility of neurology clinical trials focused on underserved stroke patient segments.

Emerging Collaborations to Enhance Neurology Clinical Trials Market Value

Strategic collaborations between academic institutions, biotech firms, and government bodies are shaping the current neurology clinical trials landscape. These partnerships enable resource sharing, accelerate patient recruitment, and support multicentre trial designs, particularly for complex neurological disorders. The ongoing rise in public-private partnerships and cross-border studies improves trial diversity and enhances the applicability of outcomes across various populations. As these collaborative models evolve, they unlock new global research opportunities, shorten development timelines, and broaden the scope, scale, and inclusivity of neurology clinical trials. This trend reflects strong market expansion potential and a progressive shift towards more integrated research ecosystems.

Neurology Clinical Trials Market Segmentation

"Neurology Clinical Trials Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Phase I
• Phase II
• Phase III
• Phase IV

Market Breakup by Indication

• Epilepsy
• Stroke
• Alzheimer's Disease (AD)
• Parkinson's Disease (PD)
• Traumatic Brain Injury (TBI)
• Amyotrophic Lateral Sclerosis (ALS)
• Others

Market Breakup by Study Design

• Interventional
• Observational
• Expanded Access

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Neurology Clinical Trials Market Share

Phase III Trials to Lead the Segmentation by Type

Phase III is expected to hold the largest market share in the segment by type. This is attributed to the high number of participants, longer trial durations, and critical role in confirming treatment efficacy and monitoring adverse effects before regulatory approval. Neurological conditions like stroke and Alzheimer’s require large-scale, evidence-based validation, making Phase III trials a priority. Increasing R&D investment, particularly from pharmaceutical giants, and growing demand for advanced neurological treatments will further boost this segment. In the forecast period, the rising pipeline of neurology drugs is poised to fuel significant growth in Phase III trials.

Stroke to Hold a Significant Neurology Clinical Trials Market Value for Segmentation by Indication

Stroke is projected to dominate the market by indication, owing to its high global prevalence and status as a leading cause of long-term disability. As per the analysis by Expert Market Research, the ischemic stroke market is expected to grow at a CAGR of 5.2% during the forecast period of 2025-2034. The urgent need for effective stroke therapies has prompted increased research funding and accelerated development of both acute and post-stroke care solutions. Advancements in drug delivery, thrombectomy procedures, and neuroprotective agents are contributing to heightened clinical activity. With regulatory bodies supporting innovation in this area and new therapeutic agents progressing through the pipeline, stroke-related trials will continue to drive market growth significantly over the coming years, reinforcing this segment’s leadership position.

Interventional Studies to Dominate the Share by Study Design

Interventional studies are set to lead the market by study design due to their direct focus on evaluating treatment efficacy through controlled environments. These trials enable precise measurement of drug impact, safety, and long-term outcomes, which is essential in complex neurological disorders. The growing need for innovative therapies in stroke, Alzheimer’s, and epilepsy is pushing sponsors to adopt interventional designs. Additionally, regulatory incentives and technological advancements in patient monitoring and biomarker integration are streamlining such trials. As more novel interventions enter the clinical phase, this segment is likely to witness sustained dominance and market value expansion.

Neurology Clinical Trials Market Analysis by Region

North America is likely to hold the largest market share, driven by strong regulatory frameworks, advanced research infrastructure, and a high burden of neurological disorders. For instance, in February 2024, the U.S. FDA approved Kisunla (donanemab-azbt) for early-stage Alzheimer’s treatment following successful trials showing statistically significant improvements across multiple cognitive and functional measures. This milestone reflects the region’s robust clinical ecosystem and readiness to support late-stage, large-scale neurology trials. Meanwhile, Europe is progressing steadily with collaborative academic studies, while Asia-Pacific is gaining traction through increased investment and trial decentralisation. However, North America’s consistent innovation pipeline cements its leading role in market development.

Leading Players in the Neurology Clinical Trials Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Supernus Pharmaceuticals, Inc

Founded in 2005 and headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of products for central nervous system (CNS) disorders, including epilepsy, ADHD, and Parkinson’s disease. Its neurology portfolio features therapies such as Trokendi XR and Oxtellar XR for seizure control. Supernus focuses on addressing unmet medical needs through differentiated therapies. The company continues to expand its pipeline in neurological and psychiatric disorders, reinforcing its role in the neurology clinical trials market through innovation and targeted treatment development across various stages of the drug development process.

AstraZeneca plc

Established in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca plc is headquartered in Cambridge, United Kingdom. The company has a strong global footprint and a diverse pharmaceutical portfolio that includes treatments for oncology, cardiovascular, and neurology. In the neurology segment, AstraZeneca continues investing in novel research, particularly in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its partnerships and collaborations with academic and biotech firms further support pipeline expansion. AstraZeneca's robust R&D infrastructure and commitment to addressing neurological conditions position it as a key player in advancing clinical trials and improving patient outcomes globally.

Aurobindo Pharma

Founded in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma is a leading pharmaceutical company known for its strong portfolio of generic and branded formulations. The company is actively involved in neurology, producing treatments for epilepsy, Parkinson’s disease, and depression. Aurobindo continues to invest in research and development for CNS therapies, aiming to enhance access and affordability worldwide. With a presence in over 150 countries and a growing number of ANDAs and biosimilars under development, Aurobindo plays an increasingly important role in neurology clinical trials, focusing on quality generics that support wider therapeutic availability.

Eisai Co., Ltd

Headquartered in Tokyo, Japan, and established in 1941, Eisai Co., Ltd is a global pharmaceutical company focused on neurology and oncology. For instance, in July 2024, Eisai, in collaboration with Biogen, presented new data at AAIC 2024 for lecanemab-irmb (LEQEMBI®), a dual-acting anti-amyloid beta protofibril antibody. LEQEMBI® is the only early-stage Alzheimer’s treatment proven to clear toxic protofibrils that persist even after plaque removal. This innovation underscores Eisai’s leadership in Alzheimer’s research. The company’s continued clinical advancements and dedicated neurology pipeline firmly establish its influential role in shaping the future of global neurology clinical trials.

Other key players in the market include Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., and Annovis Bio.

Key Questions Answered in the Neurology Clinical Trials Market

• What was the global neurology clinical trials market value in 2024?
• What is the global neurology clinical trials market forecast outlook for 2025-2034?
• What is market segmentation based on type?
• What is market segmentation based on indication?
• What is market segmentation based on study design?
• What are the major factors aiding the global neurology clinical trials market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major global neurology clinical trials market trends?
• Which type will lead the market segment?
• Which indication will lead the market segment?
• Which study design will lead the market segment?
• Who are the key players involved in the global neurology clinical trials market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?

This product will be delivered within 3-5 business days.